{"id":34872,"date":"2025-06-06T22:52:09","date_gmt":"2025-06-06T14:52:09","guid":{"rendered":"https:\/\/flcube.com\/?p=34872"},"modified":"2025-06-06T22:52:09","modified_gmt":"2025-06-06T14:52:09","slug":"biocytogens-renmab-platform-wins-japanese-patent-expanding-ip-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34872","title":{"rendered":"Biocytogen’s RenMab Platform Wins Japanese Patent, Expanding IP Portfolio"},"content":{"rendered":"\n

China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315<\/a>) announced that its RenMab platform, a key component of its fully human antibody discovery platform family, has been granted an invention patent by the Japan Patent Office (JPO). This milestone underscores Biocytogen’s commitment to advancing its global intellectual property (IP) strategy and highlights the international recognition of its core technology.<\/p>\n\n\n\n

RenMab Platform and Technology<\/strong>
RenMab mice are a cornerstone of Biocytogen’s RenMice platform family. Using its proprietary SUPCE technology, Biocytogen has replaced the variable region genes of mouse antibody heavy and light chains with human counterparts through precise in situ gene editing.<\/p>\n\n\n\n

Global Patent Strategy<\/strong>
Biocytogen continues to actively pursue global patent protection for its RenMice platform and core technologies. To date, the platform has received patent approvals in nearly 10 countries and regions, including the U.S., China, and Japan. Approximately 40 additional patent applications are under review across 15 jurisdictions, with more approvals expected soon.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that its RenMab platform, a key…<\/p>\n","protected":false},"author":1,"featured_media":34873,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[61],"tags":[1519,1214,73],"class_list":["post-34872","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-legal-ip","tag-biocytogen-pharmaceuticals","tag-hkg-2315","tag-patents"],"yoast_head":"\nBiocytogen's RenMab Platform Wins Japanese Patent, Expanding IP Portfolio - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China's Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that its RenMab platform, a key component of its fully human antibody discovery platform family, has been granted an invention patent by the Japan Patent Office (JPO). This milestone underscores Biocytogen's commitment to advancing its global intellectual property (IP) strategy and highlights the international recognition of its core technology.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34872\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biocytogen's RenMab Platform Wins Japanese Patent, Expanding IP Portfolio\" \/>\n<meta property=\"og:description\" content=\"China's Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that its RenMab platform, a key component of its fully human antibody discovery platform family, has been granted an invention patent by the Japan Patent Office (JPO). This milestone underscores Biocytogen's commitment to advancing its global intellectual property (IP) strategy and highlights the international recognition of its core technology.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34872\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-06T14:52:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0615.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34872#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34872\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biocytogen’s RenMab Platform Wins Japanese Patent, Expanding IP Portfolio\",\"datePublished\":\"2025-06-06T14:52:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34872\"},\"wordCount\":168,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34872#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0615.webp\",\"keywords\":[\"Biocytogen Pharmaceuticals\",\"HKG: 2315\",\"Patents\"],\"articleSection\":[\"Legal \\\/ IP\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34872#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34872\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34872\",\"name\":\"Biocytogen's RenMab Platform Wins Japanese Patent, Expanding IP Portfolio - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34872#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34872#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0615.webp\",\"datePublished\":\"2025-06-06T14:52:09+00:00\",\"description\":\"China's Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that its RenMab platform, a key component of its fully human antibody discovery platform family, has been granted an invention patent by the Japan Patent Office (JPO). This milestone underscores Biocytogen's commitment to advancing its global intellectual property (IP) strategy and highlights the international recognition of its core technology.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34872#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34872\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34872#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0615.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0615.webp\",\"width\":1080,\"height\":608,\"caption\":\"Biocytogen's RenMab Platform Wins Japanese Patent, Expanding IP Portfolio\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34872#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biocytogen’s RenMab Platform Wins Japanese Patent, Expanding IP Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biocytogen's RenMab Platform Wins Japanese Patent, Expanding IP Portfolio - Insight, China's Pharmaceutical Industry","description":"China's Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that its RenMab platform, a key component of its fully human antibody discovery platform family, has been granted an invention patent by the Japan Patent Office (JPO). This milestone underscores Biocytogen's commitment to advancing its global intellectual property (IP) strategy and highlights the international recognition of its core technology.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34872","og_locale":"en_US","og_type":"article","og_title":"Biocytogen's RenMab Platform Wins Japanese Patent, Expanding IP Portfolio","og_description":"China's Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that its RenMab platform, a key component of its fully human antibody discovery platform family, has been granted an invention patent by the Japan Patent Office (JPO). This milestone underscores Biocytogen's commitment to advancing its global intellectual property (IP) strategy and highlights the international recognition of its core technology.","og_url":"https:\/\/flcube.com\/?p=34872","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-06T14:52:09+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0615.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34872#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34872"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biocytogen’s RenMab Platform Wins Japanese Patent, Expanding IP Portfolio","datePublished":"2025-06-06T14:52:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34872"},"wordCount":168,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34872#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0615.webp","keywords":["Biocytogen Pharmaceuticals","HKG: 2315","Patents"],"articleSection":["Legal \/ IP"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34872#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34872","url":"https:\/\/flcube.com\/?p=34872","name":"Biocytogen's RenMab Platform Wins Japanese Patent, Expanding IP Portfolio - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34872#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34872#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0615.webp","datePublished":"2025-06-06T14:52:09+00:00","description":"China's Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that its RenMab platform, a key component of its fully human antibody discovery platform family, has been granted an invention patent by the Japan Patent Office (JPO). This milestone underscores Biocytogen's commitment to advancing its global intellectual property (IP) strategy and highlights the international recognition of its core technology.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34872#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34872"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34872#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0615.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0615.webp","width":1080,"height":608,"caption":"Biocytogen's RenMab Platform Wins Japanese Patent, Expanding IP Portfolio"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34872#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biocytogen’s RenMab Platform Wins Japanese Patent, Expanding IP Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0615.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34872","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34872"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34872\/revisions"}],"predecessor-version":[{"id":34874,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34872\/revisions\/34874"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34873"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34872"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34872"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34872"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}